Hemoglobin E Syndromes In Pakistani Population.,
2012
Aga Khan University
Hemoglobin E Syndromes In Pakistani Population., Bushra Moiz, Amna Nasir, Anila Rashid, Tariq Moatter, Mashhooda Rasool Hashmi
Department of Pathology and Laboratory Medicine
Background:Hemoglobin E is an important hemoglobin variant with a worldwide distribution. A number of hemoglobinopathies have been reported from Pakistan. However a comprehensive description of hemoglobin E syndromes for the country was never made. This study aimed to describe various hemoglobin E disorders based on hematological parameters and chromatography. The sub-aim was to characterize hemoglobin E at molecular level.
Methods:
This was a hospital based study conducted prospectively for a period of one year extending from January 1 to December 31, 2008. EDTA blood samples were analyzed for completed blood counts and hemoglobin variants through automated hematology analyzer and …
Phase I Study Of Bosutinib, A Src/Abl Tyrosine Kinase Inhibitor, Administered To Patients With Advanced Solid Tumors,
2012
H. Lee Moffitt Cancer Center and Research Institute, USA
Phase I Study Of Bosutinib, A Src/Abl Tyrosine Kinase Inhibitor, Administered To Patients With Advanced Solid Tumors, Adil Daud, Smitha Krishnamurthi, Mansoor Saleh, Barbara Gitlitz, Mitesh Borad, Philip Gold, Elena Chiorean, Gregory Springett, Richat Abbas, Shefali Agarwal
Haematology and Oncology, East Africa
Purpose: Bosutinib, a potent ATP-competitive, quinolinecarbonitrile Src/Abl kinase inhibitor, was tested in this first-in-human phase I trial in patients with advanced solid tumor malignancies.
Patients and Methods: This trial was conducted in 2 parts. In part 1 (dose escalation), increasing oral bosutinib doses were administered using a 3 + 3 design. In part 2 (dose expansion), approximately 30 patients each with refractory colorectal, pancreas, or non–small cell lung cancer were treated at the recommended phase II dose (RP2D). Primary efficacy endpoints for part 2 were median progression-free survival (colorectal and non–small cell lung) and median overall survival (pancreas).
Results: In …
Acute Myeloid Leukaemia In Children: Experience At A Tertiary Care Facility Of Pakistan,
2012
Aga Khan University
Acute Myeloid Leukaemia In Children: Experience At A Tertiary Care Facility Of Pakistan, Zehra Fadoo, Naureen Mushtaq, Saima Alvi, Muhammad Ali
Department of Paediatrics and Child Health
Objective: To document the demographics and outcome of children with Acute Myeloid Leukemia (AML) treated at a tertiary care facility of Pakistan.
Methods: A retrospective study was conducted at Aga Khan University on children (less than 15 years) diagnosed to have AML between January 2000 to May 2007.Total 40 cases were diagnosed out of which 37 charts were available for review.
Results: The average age of presentation was 8.5±4.5 years and 75% were males. The most common presenting feature was fever in 83% followed by bleeding in 41% and pallor in 39%. Initial WBC of > 100,000 was seen in 19% …
Newer Agents In Antiplatelet Therapy: A Review.,
2012
Cardeza Foundation for Hematologic Research, Department of Medicine, Thomas Jefferson University
Newer Agents In Antiplatelet Therapy: A Review., Jennifer Yeung, Michael Holinstat
Cardeza Foundation for Hematologic Research
Antiplatelet therapy remains the mainstay in preventing aberrant platelet activation in pathophysiological conditions such as myocardial infarction, ischemia, and stroke. Although there has been significant advancement in antiplatelet therapeutic approaches, aspirin still remains the gold standard treatment in the clinical setting. Limitations in safety, efficacy, and tolerability have precluded many of the antiplatelet inhibitors from use in patients. Unforeseen incidences of increased bleeding risk and recurrent arterial thrombosis observed in patients have hampered the development of superior next generation antiplatelet therapies. The pharmacokinetic and pharmacodynamic profiles have also limited the effectiveness of a number of antiplatelet inhibitors currently in use …
Regulation Of Platelet Exoctosis And Its Role In Diseases,
2012
University of Kentucky
Regulation Of Platelet Exoctosis And Its Role In Diseases, Rania A. Al Hawas
Theses and Dissertations--Health and Clinical Sciences
In addition to their role in hemostasis, platelets appear to contribute to vascular inflammatory diseases. Platelets achieve this through the secretion of various prothrombotic and pro-inflammatory molecules. Platelet secretion is mediated by integral membrane proteins called Soluble NSF Attachment protein REceptors (SNAREs). SNAREs come from both granule/vesicle membranes (v-SNAREs) and target membranes (t-SNAREs) to form a trans-bilayer complex that promotes membrane fusion and subsequent granule cargo release. The work described in this dissertation dissects various, yet related aspects of platelet secretion in both physiological relevant and pathological circumstances.
Atherosclerosis is a leading cause of death in the westernized countries and …
Effects Of Arterial Strain And Stress In The Prediction Of
Restenosis Risk: Computer Modeling Of Stent Trials,
2012
University of Nebraska-Lincoln
Effects Of Arterial Strain And Stress In The Prediction Of Restenosis Risk: Computer Modeling Of Stent Trials, Shijia Zhao, Linxia Gu, Stacey R. Froemming
Department of Mechanical and Materials Engineering: Faculty Publications
Purpose — In-stenting restenosis is one of the major complications after stenting. Clinical trials of various stent designs have reported different restenosis rates. However, quantitative correlation between stent features and restenosis statistics is scant. In this work, it is hypothesized that stress concentrations on arterial wall caused artery injury, which initiates restenosis. The goal is to assess the correlation between stent-induced arterial stress and strain and the documented restenosis rates.
Methods — Six commercially available stents, including balloon-expandable stents and self-expanding stents, were virtually implanted into the arteries through finite element method. The resulted peak Von Mises stress, principal stress, …
Utility Of Fdg Pet-Ct Scan In Determining Pathological Response To Neo-Adjuvant Chemo-Radiation Therapy In Non-Small Cell Lung Cancer (Nsclc),
2012
Lehigh Valley Health Network
Utility Of Fdg Pet-Ct Scan In Determining Pathological Response To Neo-Adjuvant Chemo-Radiation Therapy In Non-Small Cell Lung Cancer (Nsclc), Eliot L. Friedman Md, Michael F. Szwerc Md, Robert Kruklitis Md, Michael J. Weiss Mph, Robert Rienzo Md, Wen Young Md
Department of Medicine
No abstract provided.
Phase Iii Study Of Doxorubicin/Cyclophosphamide With Concomitant Versus Sequential Docetaxel As Adjuvant Treatment In Patients With Human Epidermal Growth Factor Receptor 2–Normal, Node-Positive Breast Cancer: Bcirg-005 Trial,
2011
Red Cross Clinics, Germany
Phase Iii Study Of Doxorubicin/Cyclophosphamide With Concomitant Versus Sequential Docetaxel As Adjuvant Treatment In Patients With Human Epidermal Growth Factor Receptor 2–Normal, Node-Positive Breast Cancer: Bcirg-005 Trial, Wolfgang Eiermann, Tadeusz Pienkowski, John Crown, Saeed Sadeghi, Miguel Martin, Arlene Chan, Mansoor Saleh, Sandeep Sehdev, Louise Provencher, Vladimir Semiglazov
Haematology and Oncology, East Africa
Purpose: Anthracyclines, taxanes, and alkylating agents are among the most active agents in treatment of adjuvant breast cancer (BC), but the optimal schedule for their administration is unknown. We performed an adjuvant trial to compare the sequential regimen of doxorubicin with cyclophosphamide (AC) followed by docetaxel (ie, AC>T) with the combination regimen of TAC.
Patients and Methods: Women with node-positive, human epidermal growth factor receptor 2–nonamplified, operable BC were stratified by number of axillary nodes and hormone receptor status and were randomly assigned to adjuvant chemotherapy with six cycles of TAC (75/50/500 mg/m2 every 3 weeks) or four cycles …
Transfection Of Human Platelets With Short Interfering Rna.,
2011
Thomas Jefferson University
Transfection Of Human Platelets With Short Interfering Rna., Wei Hong, Altaf A Kondkar, Srikanth Nagalla, Wolfgang Bergmeier, Ying Jin, Jay Herman, Paul Bray
Cardeza Foundation for Hematologic Research
Platelets contain mRNAs and are capable of translating mRNA into protein, and it has been previously demonstrated that platelets increase their levels of integrin β3 overtime while in blood bank storage conditions. We are unaware of prior attempts to introduce nucleic acids into platelets. Considering the potential clinical and research utility of manipulating platelet gene expression, we tested whether small interfering RNAs (siRNAs) could be transfected into normal human platelets. Multiple conditions were tested, including lipofectamine versus electroporation, different amounts of siRNA, the effect of different buffers and the presence of plasma during transfection, and the time for optimal siRNA …
Randomized Phase Iii Trial Of Paclitaxel/Carboplatin With Or Without Pf-3512676 (Toll-Like Receptor 9 Agonist) As First-Line Treatment For Advanced Non–Small-Cell Lung Cancer,
2011
McGill University Health Centre, Canada
Randomized Phase Iii Trial Of Paclitaxel/Carboplatin With Or Without Pf-3512676 (Toll-Like Receptor 9 Agonist) As First-Line Treatment For Advanced Non–Small-Cell Lung Cancer, Vera Hirsh, Luis Paz-Ares, Michael Boyer, Rafael Rosell, Gary Middleton, Wilfried Eberhardt, Aleksandra Szczesna, Pavel Reiterer, Mansoor Saleh, Oscar Arrieta
Haematology and Oncology, East Africa
Purpose: This phase III study examined efficacy of the synthetic Toll-like receptor 9–activating oligodeoxynucleotide PF-3512676 in combination with standard paclitaxel/carboplatin chemotherapy in patients with advanced non–small-cell lung cancer (NSCLC).
Patients and Methods: Chemotherapy-naive patients with stage IIIB or IV NSCLC were randomly assigned (1:1) to receive up to six courses of paclitaxel/carboplatin (intravenous paclitaxel 200 mg/m2 and carboplatin at area under the [concentration-time] curve 6 on day 1 of a 3-week cycle) alone (control arm) or in combination with 0.2 mg/kg subcutaneous PF-3512676 on days 8 and 15 (investigational arm). Primary end point was overall survival (OS).
Results: Baseline demographics …
Sunitinib Plus Paclitaxel Versus Bevacizumab Plus Paclitaxel For First-Line Treatment Of Patients With Advanced Breast Cancer: A Phase Iii, Randomized, Open-Label Trial,
2011
Virginia Cancer Specialists, USA
Sunitinib Plus Paclitaxel Versus Bevacizumab Plus Paclitaxel For First-Line Treatment Of Patients With Advanced Breast Cancer: A Phase Iii, Randomized, Open-Label Trial, Nicholas Robert, Mansoor Saleh, Devchand Paul, Daniele Generali, Laurent Gressot, Mehmet Copur, Adam Brufsky, Susan Minton, Jeffrey Giguere, John W. Smith Ii
Haematology and Oncology, East Africa
Introduction: A multicenter, open-label phase III study was conducted to test whether sunitinib plus paclitaxel prolongs progression-free survival (PFS) compared with bevacizumab plus paclitaxel as first-line treatment for patients with HER2− advanced breast cancer.
Patients and Methods: Patients with HER2− advanced breast cancer who were disease free for ≥ 12 months after adjuvant taxane treatment were randomized (1:1; planned enrollment 740 patients) to receive intravenous (I.V.) paclitaxel 90 mg/m2 every week for 3 weeks in 4-week cycles plus either sunitinib 25 to 37.5 mg every day or bevacizumab 10 mg/kg I.V. every 2 weeks.
Results: The trial was terminated early …
Septic Shock: Current Management And New Therapeutic Frontiers,
2011
Robert Wood Johnson School of Medicine
Septic Shock: Current Management And New Therapeutic Frontiers, R. Phillip Dellinger, Md
Division of Pulmonary, Allergy, and Critical Care Medicine Presentations and Grand Rounds
No audio is available for this presentation.
Dr. R. Phillip Dellinger is a Professor of Medicine who holds a faculty appointment in the Division of Pulmonary and Critical Care Medicine at the Robert Wood Johnson School of Medicine, University of Medicine and Dentistry of New Jersey. He is also the Vice-Chair, Department of Medicine and the Director, Medical/Surgical/Cardiovascular Surgical Intensive Care Unit at the Cooper Medical Center in Camden New Jersey. In 2006-2007, he was selected as South Jersey Top Docs by South Jersey Magazine. Dr. Dellinger's interests are in the treatment and outcomes of septic shock.
Incidence And Impact Of Baseline Electrolyte Abnormalities In Patients Admitted With Chemotherapy Induced Febrile Neutropenia.,
2011
Aga Khan University
Incidence And Impact Of Baseline Electrolyte Abnormalities In Patients Admitted With Chemotherapy Induced Febrile Neutropenia., Asim Jamal Shaikh, Samira Ahmed Bawany, Nehal Masood, Ausaf Ahmed Khan, Ahmed Nadeem Abbasi, Syed Najeeb Niamutullah, Adnan Zaidi, Salman Adil, Shiyam Kumar
Section of Haematology/Oncology
Background: Febrile neutropenia (FN) and myelosupression remain a challenging oncologic medical emergency and dose limiting toxicity associated with chemotherapy for cancers. Various factors are known to affect the outcomes for Patients diagnosed with FN. Electrolyte abnormalities have commonly been observed, but the real incidence and their impact has been only scarcely studied in literature. Methods: This was a prospective, observational study. A total of two hundred and fifteen (215) Patients admitted between January 2007 and August 2008 were included. Analysis of data was made using SPSS version16.0. Toxicity profile was graded according to CTC version 3.0. Results: Almost equal number …
The Nurse's Knowledge Of Blood Conservation As A Part Of Blood Management,
2011
Gardner-Webb University
The Nurse's Knowledge Of Blood Conservation As A Part Of Blood Management, Lindsey Putnam Austin
Nursing Theses and Capstone Projects
Medicine has historically regarded blood transfusion as an integral component of major surgery or illness. However, clinical studies have shown that allogeneic blood transfusions are associated with increased morbidity and decreased survival. Knowledge of this research and the concepts of blood conservation so as to avoid unnecessary blood transfusions is needed in order to deliver holistic care and serve as patient advocate. This knowledge reaches every specialty of nursing care.
This study of the nurse's knowledge of blood conservation as a part of blood management utilizes The Conservation Model developed by Myra E. Levine in 1973. Levine's work is a …
Identification Of Genes Involved In Hematopoietic Stem Cell Differentiation And Leukemia Differentiation And Leukemia,
2011
Marshall University
Identification Of Genes Involved In Hematopoietic Stem Cell Differentiation And Leukemia Differentiation And Leukemia, Jasjeet Bhullar
Theses, Dissertations and Capstones
Hematopoiesis is maintained by a proper balance between self renewal and multipotent differentiation of the hematopoietic stem cells (HSC). Acute myelogenous leukemia (AML) is characterized by the blockage in the differentiation of HSC, while self renewal and proliferation is preserved. It is important to understand the mechanisms involved in the inhibition of hematopoietic differentiation and maintenance of the HSC state in order to develop better therapies for AML. In these studies I have explored the role of Hsp90, omega-3 fatty acids and YB-1 in hematopoietic differentiation. EML, a hematopoietic precursor cell line, was used as a model for the hematopoietic …
Eltrombopag For Management Of Chronic Immune Thrombocytopenia (Raise): A 6-Month, Randomised, Phase 3 Study,
2011
Prince of Wales Hospital, China
Eltrombopag For Management Of Chronic Immune Thrombocytopenia (Raise): A 6-Month, Randomised, Phase 3 Study, Gregory Cheng, Mansoor Saleh, Claus Marcher, Sandra Vasey, Bhabita Mayer, Manuel Aivado, Michael Arning, Nicole Stone, James Bussel
Haematology and Oncology, East Africa
Background: Eltrombopag is an oral thrombopoietin receptor agonist for the treatment of thrombocytopenia. We aimed to compare the response to once daily eltrombopag versus placebo in patients with chronic immune thrombocytopenia during a 6-month period.
Methods: We undertook a phase 3, double-blind, placebo-controlled study in adults with previously treated immune thrombocytopenia of more than 6 months’ duration who had baseline platelet counts lower than 30 000 per μL. Patients were randomly allocated (in a 2:1 ratio) treatment with local standard of care plus 50 mg eltrombopag or matching placebo once daily for 6 months. Randomisation was done centrally with a …
Pemetrexed With Or Without Matuzumab As Second-Line Treatment For Patients With Stage Iiib/Iv Non-Small Cell Lung Cancer,
2010
University of Texas Southwestern Medical Center, USA
Pemetrexed With Or Without Matuzumab As Second-Line Treatment For Patients With Stage Iiib/Iv Non-Small Cell Lung Cancer, Joan Schiller, Joachim Von Pawel, Philipp Schütt, Rafat Ansari, Michael Bijoy Thomas, Mansoor Saleh, Robert D. Mccroskey, Wolfgang Pfeife, Thomas Marsland, Goetz Kloecker
Haematology and Oncology, East Africa
Introduction: This randomized phase II study investigated pemetrexed in combination with the epidermal growth factor receptor (EGFR)-targeting monoclonal antibody matuzumab compared with pemetrexed alone as second-line therapy for patients with advanced non-small cell lung cancer.
Methods: Patients received pemetrexed 500 mg/m2 every 3 weeks either alone (n = 50) or in combination with matuzumab at either 800 mg weekly (n = 51) or 1600 mg every 3 weeks (n = 47). The primary end point was objective response, as assessed by an independent review committee.
Results: Tumor EGFR expression was detected in 87% of randomized patients. The objective response rate …
Phase Iii, Randomized, Double-Blind, Placebo-Controlled Evaluation Of Pregabalin For Alleviating Hot Flashes, N07c1,
2010
Mayo Clinic, Rochester
Phase Iii, Randomized, Double-Blind, Placebo-Controlled Evaluation Of Pregabalin For Alleviating Hot Flashes, N07c1, Charles L. Loprinzi, Rui Qin, Ernie P. Baclueva, Donald J. Jurgens
Articles
PURPOSE:
Hot flashes are a common problem for which effective and safe treatments are needed. The current trial was conducted on the basis of preliminary promising data that pregabalin decreased hot flashes.
PATIENTS AND METHODS:
A double-blind, placebo-controlled, randomized trial design was used to compare pregabalin at target doses of 75 mg twice daily and 150 mg twice daily with a placebo. Hot flash frequencies and scores (frequency times mean severity) were recorded daily during a baseline week and for six treatment weeks. The primary end point for this study was the change-from-baseline hot flash score during treatment week 6 …
Rhnull: A Rare Blood Group Phenotype,
2010
Aga Khan University
Rhnull: A Rare Blood Group Phenotype, Adnan Qureshi, Muhammad Salman, Bushra Moiz
Section of Internal Medicine
Rhnull phenotype is a rare blood group characterized by the lack of expression of all Rh antigens (D, C, c, E and e) on the red cells. The phenotype is further classified into the regulator and amorph type based on underlying genetic defect. The clinical significance of its recognition is that such patients suffer from Rhnull syndrome associated with osmotically fragile red cells called stomatocytes with subsequent chronic haemolytic anaemia of varying degree. Another importance is that such subjects readily form alloantibodies on exposure to Rh antigens. We report herein rare Rhaull phenotype in a young pregnant female which was …
Acute Lymphoblastic Leukemia Subsequent To Temozolomide Use In A 26-Year-Old Man: A Case Report.,
2010
Aga Khan University
Acute Lymphoblastic Leukemia Subsequent To Temozolomide Use In A 26-Year-Old Man: A Case Report., Asim Jamal Shaikh, Nehal Masood
Section of Haematology/Oncology
Introduction: We report the development of acute lymphoblastic leukemia in a Patient in whom temozolomide was used for the treatment of a brain tumor. Unlike that of other alkylating agents, the leukemogenic potential of temozolomide is considered to be very low, and very rarely are such cases reported. Case Presentation: A 26-year-old Pakistani man who was treated for glioblastoma with temozolomide in an adjuvant setting was diagnosed to have acute lymphoblastic leukemia one year after stopping temozolomide. Conclusion: Temozolomide is a highly active agent, used in the management of high-grade brain neoplasms. The agent is generally regarded to be safe, …
